Issue
Date Log
Copyright (c) 2026 Sultan Essa Alhatheg, Ebtehal Hamod Ali, Motaen Darwish Hasan Fageh, Hussam Mohammed Nasser Zawli, Mai Awadh Saeed Alrashidi, Mansour Hassan Ali Alshehri, Suoad Albalawi, Ashwag Mohammed Alasmarei, Yassir Mohammad Jabbari, Albader Mohammed Moafa, Mohammed Dughyyim Alharbi, Leena Mabrouk Alzaid

This work is licensed under a Creative Commons Attribution 4.0 International License.
The Role of Nurses and Pharmacists in Managing Antimicrobial Practices in Patients with Hospital-Acquired Pneumonia
Corresponding Author(s) : Sultan Essa Alhatheg
Saudi Journal of Medicine and Public Health,
Vol. 3 No. 1 (2026)
Abstract
Background: Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are major healthcare-associated infections that contribute to morbidity, mortality, prolonged hospitalization, and increased healthcare costs. Their management is complicated by multidrug-resistant pathogens, diagnostic limitations, and the clinical complexity of hospitalized patients.
Aim: This review examines the epidemiology, etiology, clinical presentation, diagnostic evaluation, treatment, and prognosis of HAP and VAP, with particular emphasis on the complementary roles of nursing and pharmacy professionals in prevention and management.
Methods: The review discusses current evidence concerning common bacterial pathogens, risk factors for antimicrobial resistance, clinical and microbiological diagnostic approaches, empirical antimicrobial selection, treatment modification, and infection prevention strategies. It also examines nursing surveillance, medication optimization, antimicrobial stewardship, and multidisciplinary collaboration.
Results: HAP and VAP are commonly associated with gram-negative organisms, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter species, as well as Staphylococcus aureus. Previous intravenous antibiotic exposure and prolonged hospitalization increase the risk of resistant infections. Diagnosis requires integration of clinical findings, radiological evidence, and respiratory cultures, while molecular assays may accelerate pathogen identification. Empirical treatment should reflect local resistance patterns and individual risk factors, followed by culture-guided de-escalation. A seven-day antibiotic course is generally sufficient for uncomplicated cases. Nursing interventions support early detection and infection prevention, whereas pharmacists optimize antimicrobial selection, dosing, safety, and treatment duration.
Conclusion: Effective HAP and VAP management requires early diagnosis, appropriate antimicrobial therapy, infection prevention, and coordinated interprofessional care.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- 1. Kumar ST, Yassin A, Bhowmick T, Dixit D. Recommendations From the 2016 Guidelines for the Management of Adults With Hospital-Acquired or Ventilator-Associated Pneumonia. P T. 2017 Dec;42(12):767-772.
- 2. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 01;63(5):575-82.
- 3. Erb CT, Patel B, Orr JE, Bice T, Richards JB, Metersky ML, Wilson KC, Thomson CC. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. Ann Am Thorac Soc. 2016 Dec;13(12):2258-2260.
- 4. Fagon JY. Hospital-acquired pneumonia: diagnostic strategies: lessons from clinical trials. Infect Dis Clin North Am. 2003 Dec;17(4):717-26.
- 5. Luyt CE, Chastre J, Fagon JY. Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med. 2004 May;30(5):844-52.
- 6. Heyland DK, Cook DJ, Marshall J, Heule M, Guslits B, Lang J, Jaeschke R. The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Canadian Critical Care Trials Group. Chest. 1999 Apr;115(4):1076-84.
- 7. Baselski VS, el-Torky M, Coalson JJ, Griffin JP. The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia. Chest. 1992 Nov;102(5 Suppl 1):571S-579S.
- 8. Burrack-Lange SC, Personne Y, Huber M, Winkler E, Weile J, Knabbe C, Görig J, Rohde H. Multicenter assessment of the rapid Unyvero Blood Culture molecular assay. J Med Microbiol. 2018 Sep;67(9):1294-1301.
- 9. Luyt CE, Hékimian G, Koulenti D, Chastre J. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care. 2018 Oct;24(5):332-338.
- 10. Karakuzu Z, Iscimen R, Akalin H, Kelebek Girgin N, Kahveci F, Sinirtas M. Prognostic Risk Factors in Ventilator-Associated Pneumonia. Med Sci Monit. 2018 Mar 05;24:1321-1328.
References
1. Kumar ST, Yassin A, Bhowmick T, Dixit D. Recommendations From the 2016 Guidelines for the Management of Adults With Hospital-Acquired or Ventilator-Associated Pneumonia. P T. 2017 Dec;42(12):767-772.
2. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 01;63(5):575-82.
3. Erb CT, Patel B, Orr JE, Bice T, Richards JB, Metersky ML, Wilson KC, Thomson CC. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. Ann Am Thorac Soc. 2016 Dec;13(12):2258-2260.
4. Fagon JY. Hospital-acquired pneumonia: diagnostic strategies: lessons from clinical trials. Infect Dis Clin North Am. 2003 Dec;17(4):717-26.
5. Luyt CE, Chastre J, Fagon JY. Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med. 2004 May;30(5):844-52.
6. Heyland DK, Cook DJ, Marshall J, Heule M, Guslits B, Lang J, Jaeschke R. The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Canadian Critical Care Trials Group. Chest. 1999 Apr;115(4):1076-84.
7. Baselski VS, el-Torky M, Coalson JJ, Griffin JP. The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia. Chest. 1992 Nov;102(5 Suppl 1):571S-579S.
8. Burrack-Lange SC, Personne Y, Huber M, Winkler E, Weile J, Knabbe C, Görig J, Rohde H. Multicenter assessment of the rapid Unyvero Blood Culture molecular assay. J Med Microbiol. 2018 Sep;67(9):1294-1301.
9. Luyt CE, Hékimian G, Koulenti D, Chastre J. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care. 2018 Oct;24(5):332-338.
10. Karakuzu Z, Iscimen R, Akalin H, Kelebek Girgin N, Kahveci F, Sinirtas M. Prognostic Risk Factors in Ventilator-Associated Pneumonia. Med Sci Monit. 2018 Mar 05;24:1321-1328.